What core pharmacology, dosing, administration, safety profile, and clinical use of semaglutide (GLP‑1 receptor agonist) should I learn to practice?

Core Knowledge for Practicing with Semaglutide

Semaglutide is a once-weekly GLP-1 receptor agonist that requires slow dose titration, proper injection technique, and careful management of gastrointestinal side effects to maximize adherence and therapeutic benefit. 1

Mechanism of Action & Clinical Effects

Semaglutide works through multiple pathways:

• Glucose control: Enhances insulin secretion, suppresses glucagon, slows gastric emptying
• Weight loss: Reduces appetite and food intake centrally; achieves 14.9% mean weight reduction at 2.4 mg weekly dose 2
• Cardiovascular protection: Direct effects on sinoatrial node, arterial endothelium, and autonomic nervous system; reduces major adverse cardiovascular events by 26% (HR 0.74) even in non-diabetic patients with cardiovascular disease 2

The half-life is 7 days, reaching steady state in 4-5 weeks 3.

Dosing & Administration

Injectable Formulation (Subcutaneous)

Start low and titrate slowly to minimize gastrointestinal intolerance 1:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Week 9+: 1 mg weekly (maintenance for diabetes)
• For obesity: Can escalate to 2.4 mg weekly after 1 mg dose

Oral Formulation

• Days 1-30: 3 mg daily
• Days 31-60: 7 mg daily
• Day 61+: 14 mg daily (target dose)

Critical administration rule for oral: Take on empty stomach with ≤4 oz water, wait 30 minutes before eating/drinking/other medications 4, 5.

Injection Technique Details

From FDA labeling 6:

• Use NovoFine Plus or NovoFine needles (up to 8 mm length)
• Always use new needle for each injection - reduces contamination, infection, leakage, and dosing errors
• Check flow with each new pen (flow check symbol)
• Inject subcutaneously in abdomen, thigh, or upper arm
• Never share pens even with needle change - serious infection risk
• Store unused pens refrigerated (36-46°F); in-use pens can be room temperature (59-86°F) for 56 days maximum
• Discard pen after 56 days regardless of remaining medication

Adverse Effects & Management

Gastrointestinal (Most Common)

Nausea, vomiting, diarrhea are dose-dependent and most prominent at initiation 2, 1. Management strategies:

• Slow titration is essential - this is your primary mitigation tool
• Eat smaller meals, stop when not hungry
• Avoid spicy foods, high-fat diet, alcohol, carbonated drinks
• Symptoms typically improve over time with continued use

Serious but Rare

• Acute pancreatitis: Use with caution in patients with prior pancreatitis history 2
• Retinopathy worsening: Occurs with rapid glucose reduction in patients with marked hyperglycemia and pre-existing retinopathy - ensure regular ophthalmology follow-up in these patients 1
• Gallbladder disorders: Rarely symptomatic 2
• Cardiac arrhythmia/tachycardia: Monitor if symptomatic; consider beta-blockers 2

Hypoglycemia Risk

Adjust concomitant glucose-lowering medications 1:

• Reduce insulin secretagogues (sulfonylureas, meglitinides) and/or insulin doses when starting semaglutide
• Risk highest when eGFR >45 mL/min/1.73m² or A1c near target
• Increase self-monitoring and patient education on hypoglycemia symptoms

Drug Interactions

Delayed gastric emptying affects oral medication absorption 3:

• May impact timing-sensitive oral medications
• No specific dose adjustments required for semaglutide itself
• Consider timing of other oral medications relative to semaglutide administration

Discontinue DPP-4 inhibitors when starting semaglutide - redundant incretin-based therapy 1.

Cardiovascular & Renal Benefits

Prescribe for cardiorenal risk reduction, not just glucose control 1:

• Proven mortality benefit in SUSTAIN 6 (RR 0.74 for MACE) 2
• Benefits extend to non-diabetic patients with cardiovascular disease 2
• Cardiorenal protection maintained even with reduced kidney function (eGFR >20-25 mL/min/1.73m²) 1

Common Pitfalls to Avoid

1. Titrating too quickly - primary cause of discontinuation due to GI intolerance
2. Not adjusting insulin/sulfonylureas - leads to hypoglycemia
3. Sharing pens or reusing needles - infection risk
4. Forgetting 56-day disposal rule - medication degradation
5. Inadequate patient education on injection technique - leads to dosing errors and poor adherence
6. Not monitoring patients with pre-existing retinopathy - risk of worsening with rapid glucose reduction

Patient Selection

Ideal candidates:

• Type 2 diabetes requiring additional glucose control
• Obesity (BMI ≥27 with comorbidity or ≥30)
• Established cardiovascular disease or high cardiovascular risk
• Desire for weight loss
• Preference for once-weekly dosing

Avoid or use extreme caution:

• Personal/family history of medullary thyroid carcinoma or MEN 2
• History of pancreatitis (relative contraindication)
• Gastroparesis
• Severe gastrointestinal disease

Monitoring Parameters

• Weight and BMI: Track at each visit
• A1c: Every 3 months until stable, then every 6 months
• Blood pressure and lipids: Periodically
• Renal function: Baseline and periodically
• Ophthalmology: Regular exams, especially if rapid glucose reduction in patients with retinopathy
• Adherence and tolerability: At each visit